Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
MWN-AI** Summary
Rafael Holdings, Inc. (NYSE: RFL) released its financial results for the third quarter and first nine months of fiscal 2025, which ended on April 30, 2025. The company, based in Newark, New Jersey, reported a net loss of $4.8 million, or $0.19 per share, for the third quarter, a significant improvement from the $32.4 million loss, or $1.36 per share, for the same period last year. The CEO, Howard Jonas, highlighted the successful merger with Cyclo Therapeutics and noted that the company is anticipating the release of pivotal Phase 3 study data for its treatment candidate for Niemann-Pick Disease, Trappsol® Cyclo™, by month's end.
As of April 30, 2025, Rafael Holdings boasted cash and equivalents of $37.9 million, bolstered by a $25 million rights offering that concluded on June 4, 2025. The rights offering yielded net proceeds of $24.9 million. Year-over-year, research and development expenses increased to $3.0 million from $1.5 million, while general and administrative expenses rose to $3.2 million from $1.9 million, reflecting the operational inclusion of Cyclo Therapeutics.
For the nine-month period, the company experienced a net loss of $18.4 million, or $0.73 per share, down from a $29.9 million loss, or $1.26 per share, in the prior year. The results indicate a shift in financial performance, primarily due to decreased net losses attributed to reduced unrealized losses from investments in Cyclo equity.
Rafael Holdings continues to focus on advancing its clinical products while maintaining a strong financial position post-merger, promising to remain a pivotal player in the biotechnology landscape.
MWN-AI** Analysis
Rafael Holdings, Inc. (NYSE: RFL) has reported improved financial results for the third quarter of fiscal 2025, marked by a substantial decrease in net losses and enhanced liquidity following the completion of its merger with Cyclo Therapeutics. The company has strategically positioned itself to leverage the development of its lead candidate, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C1, a rare genetic condition.
Key financial highlights indicate a reduction in net loss to $4.8 million, translating to $0.19 per share, a notable improvement from $32.4 million loss in the prior year’s quarter. This decrease can be largely attributed to the absence of significant unrealized losses seen last year and the successful closing of a $25 million rights offering, bolstering cash reserves to nearly $38 million. This liquidity is pivotal for Rafael Holdings as it progresses towards potential clinical milestones.
Investors should note the increased research and development (R&D) expenditure of $3.0 million, reflecting consolidated operations post-merger and ongoing trials. Such investments in R&D signal the company’s commitment to advancing Trappsol® Cyclo™, which could open doors for substantial returns, particularly if trial results are favorable.
However, investors must remain cognizant of the ongoing risk factors associated with biotech firms, especially those in clinical phases. The financial statements reflect significant operational costs, and the absence of consistent revenue streams remains a concern. While the decrease in losses is promising, the pathway to profitability is contingent upon successful clinical outcomes and subsequent regulatory permissions.
In conclusion, Rafael Holdings is in a transformative phase with potential upside driven by its robust pipeline and enhanced financial position. However, prospective investors should weigh the inherent risks against the opportunity for future gains, particularly in the context of upcoming interim analysis data from pivotal trials expected later this month.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEWARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT), today reported its financial results for the third quarter and first nine months of fiscal year 2025 ended April 30, 2025.
“We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48-week interim analysis of the pivotal Phase 3 TransportNPC ™ study evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated later this month,” said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, “We have enhanced our financial position with the closing of a $25 million rights offering earlier this month which will support advancing this potential new treatment option for patients suffering from this rare genetic disease.”
Rafael Holdings, Inc. Third Quarter Fiscal Year 2025 Financial Results
As of April 30, 2025, we had cash and cash equivalents of $37.9 million. On June 4, 2025, the Company announced the closing of a $25 million rights offering, which, including the funding of the backstop commitment by the Jonas family, raised net proceeds of $24.9 million after deduction of certain expenses incurred in connection with the offering.
For the three months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $4.8 million, or $0.19 per share, versus a net loss of $32.4 million, or $1.36 per share in the year ago period. The year over year decrease in net loss is attributable to non-cash items, primarily unrealized losses of $1.4 million on the Company’s investment in Cyclo equity which we purchased in advance of the potential merger in the current period versus $4.4 million in the year ago period, combined with an in-process R&D expense of $89.9 million related to the acquisition of Cornerstone, partially offset by a $31.3 million recovery of receivables from Cornerstone in the year ago period.
Research and development expenses were $3.0 million for the three months ended April 30, 2025, compared to $1.5 million in the year ago period. The year over year increase relates to the inclusion in the current year period of spending at Cyclo Therapeutics following the March 25, 2025 merger and the activity of Cornerstone and Day Three which were consolidated with Rafael Holdings during fiscal 2024.
General and administrative expenses were $3.2 million for the three months ended April 30, 2025, compared to $1.9 million in the year ago period. The year over year increase relates to the inclusion of Cyclo Therapeutics following closing of the merger, and the activity of Cornerstone and Day Three, following their consolidation.
Rafael Holdings, Inc. First Nine Months Fiscal Year 2025 Financial Results
For the nine months ended April 30, 2025, we recorded a net loss attributable to Rafael Holdings of $18.4 million, or $0.73 per share, versus a net loss of $29.9 million, or $1.26 per share in the year ago period. The year over year decrease in net loss is attributable to in-process R&D expense of $89.9 million related to the acquisition of Cornerstone net with a $31.3 million recovery of receivables from Cornerstone in the year ago period and $3.2 million in unrealized gains on the Company’s investment in Cyclo equity.
Research and development expenses were $5.3 million for the nine months ended April 30, 2025, compared to $2.6 million in the year ago period. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024.
For the nine months ended April 30, 2025, general and administrative expenses were $8.3 million compared to $6.5 million in the same period in the prior year. The year over year increase relates to the merger with Cyclo Therapeutics which closed on March 25, 2025, and the activity of Cornerstone and Day Three, which were consolidated with Rafael Holdings during fiscal 2024.
About Rafael Holdings, Inc.
Rafael Holdings, Inc. holds interests in clinical and early-stage pharmaceutical and certain other companies, including our wholly owned subsidiary, Cyclo Therapeutics, LLC, a clinical stage biotechnology company dedicated to developing Rafael’s lead clinical candidate, Trappsol ® Cyclo™, which is being evaluated in clinical trials for the potential treatment of Niemann-Pick Disease Type C1 (“NPC1”), a rare, fatal, and progressive genetic disorder. Rafael also holds majority equity interests in LipoMedix Pharmaceuticals Ltd., a clinical stage pharmaceutical company, Cornerstone Pharmaceuticals, Inc., formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company, Rafael Medical Devices, LLC, an orthopedic-focused medical device company developing instruments to advance minimally invasive surgeries, and Day Three Labs, Inc., a company which empowers third-party manufacturers to reimagine their existing cannabis offerings.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended July 31, 2024, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Contact:
Barbara Ryan
Barbara.ryan@rafaelholdings.com
(203) 274-2825
| RAFAEL HOLDINGS, INC. | |||||||||
| CONSOLIDATED BALANCE SHEETS | |||||||||
| (in thousands, except share and per share data) | |||||||||
| April 30, 2025 | July 31, 2024 | ||||||||
| (audited) | |||||||||
| ASSETS | |||||||||
| CURRENT ASSETS | |||||||||
| Cash and cash equivalents | $ | 37,936 | $ | 2,675 | |||||
| Available-for-sale securities | — | 63,265 | |||||||
| Interest receivable | — | 515 | |||||||
| Prepaid clinical trial costs | 2,968 | — | |||||||
| Convertible note receivables, due from Cyclo | — | 5,191 | |||||||
| Accounts receivable, net of allowance for credit losses of $245 at April 30, 2025 and July 31, 2024 | 414 | 426 | |||||||
| Inventory | 288 | — | |||||||
| Prepaid expenses and other current assets | 837 | 430 | |||||||
| Total current assets | 42,443 | 72,502 | |||||||
| Property and equipment, net | 1,614 | 2,120 | |||||||
| Non-current prepaid clinical trial costs | 1,399 | — | |||||||
| Investments – Cyclo | — | 12,010 | |||||||
| Investments - Hedge Funds | — | 2,547 | |||||||
| Convertible note receivable classified as available-for-sale | 1,719 | 1,146 | |||||||
| Goodwill | 28,278 | 3,050 | |||||||
| Intangible assets, net | 1,027 | 1,847 | |||||||
| In-process research and development | 31,575 | 1,575 | |||||||
| Other assets | 41 | 35 | |||||||
| TOTAL ASSETS | $ | 108,096 | $ | 96,832 | |||||
| LIABILITIES AND EQUITY | |||||||||
| CURRENT LIABILITIES | |||||||||
| Accounts payable | $ | 7,793 | $ | 2,556 | |||||
| Accrued expenses | 1,866 | 1,798 | |||||||
| Convertible notes payable | 614 | 614 | |||||||
| Other current liabilities | 93 | 113 | |||||||
| Due to related parties | 664 | 733 | |||||||
| Installment note payable | — | 1,700 | |||||||
| Total current liabilities | 11,030 | 7,514 | |||||||
| Accrued expenses, noncurrent | 3,445 | 2,982 | |||||||
| Convertible notes payable, noncurrent | 76 | 73 | |||||||
| Other liabilities | 25 | 5 | |||||||
| Deferred income tax liability | 9,002 | — | |||||||
| TOTAL LIABILITIES | 23,578 | 10,574 | |||||||
| COMMITMENTS AND CONTINGENCIES | |||||||||
| EQUITY | |||||||||
| Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of April 30, 2025 and July 31, 2024 | 8 | 8 | |||||||
| Class B common stock, $0.01 par value; 200,000,000 shares authorized, 31,240,188 issued and outstanding (excluding treasury shares of 101,487) as of April 30, 2025, and 24,142,535 issued and 23,819,948 outstanding (excluding treasury shares of 101,487) as of July 31, 2024 | 312 | 238 | |||||||
| Additional paid-in capital | 296,648 | 280,048 | |||||||
| Accumulated deficit | (220,169 | ) | (201,743 | ) | |||||
| Treasury stock, at cost; 101,487 Class B shares as of October 31, 2024 and July 31, 2024 | (168 | ) | (168 | ) | |||||
| Accumulated other comprehensive income related to unrealized income on available-for-sale securities | 219 | 111 | |||||||
| Accumulated other comprehensive income related to foreign currency translation adjustment | 3,728 | 3,691 | |||||||
| Total equity attributable to Rafael Holdings, Inc. | 80,578 | 82,185 | |||||||
| Noncontrolling interests | 3,940 | 4,073 | |||||||
| TOTAL EQUITY | 84,518 | 86,258 | |||||||
| TOTAL LIABILITIES AND EQUITY | $ | 108,096 | $ | 96,832 | |||||
| RAFAEL HOLDINGS, INC. | ||||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||||||||||
| (unaudited, in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended April 30, | Nine Months Ended April 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues | $ | 362 | $ | 336 | $ | 567 | $ | 472 | ||||||||
| Cost of Infusion Technology revenue | 31 | 85 | 106 | 85 | ||||||||||||
| Cost of product revenue | 9 | — | 9 | — | ||||||||||||
| SG&A Expenses | 3,170 | 1,923 | 8,284 | 6,524 | ||||||||||||
| R&D Expenses | 3,003 | 1,526 | 5,276 | 2,627 | ||||||||||||
| In-process R&D expense | — | 89,861 | — | 89,861 | ||||||||||||
| Depreciation and amortization | 62 | 102 | 238 | 157 | ||||||||||||
| Loss on impairment of goodwill | — | — | 3,050 | — | ||||||||||||
| Operating Loss | (5,913 | ) | (93,161 | ) | (16,396 | ) | (98,782 | ) | ||||||||
| Interest income | 472 | 502 | 1,529 | 1,777 | ||||||||||||
| Loss on initial investment in Day Three upon acquisition | — | — | — | (1,633 | ) | |||||||||||
| Realized gain on available-for-sale securities | — | 945 | 178 | 1,521 | ||||||||||||
| Realized loss on investment in equity securities | — | — | — | (46 | ) | |||||||||||
| Realized gain on investment - Cyclo | — | — | — | 424 | ||||||||||||
| Unrealized (loss) gain on investments - Cyclo | (1,393 | ) | (4,395 | ) | (5,144 | ) | 3,199 | |||||||||
| Unrealized gain (loss) on convertible notes receivable, due from Cyclo | 383 | — | (719 | ) | — | |||||||||||
| Unrealized loss on investments - Hedge Funds | — | (3 | ) | — | (118 | ) | ||||||||||
| Recovery of receivables from Cornerstone | — | 31,305 | — | 31,305 | ||||||||||||
| Interest expense | (165 | ) | (85 | ) | (490 | ) | (85 | ) | ||||||||
| Other income, net | 154 | — | 74 | 118 | ||||||||||||
| Loss before Incomes Taxes | (6,462 | ) | (64,892 | ) | (20,968 | ) | (62,320 | ) | ||||||||
| Benefit from income taxes | 2,411 | 2,599 | 2,379 | 2,593 | ||||||||||||
| Equity in loss of Day Three | — | — | — | (422 | ) | |||||||||||
| Consolidated net loss | (4,051 | ) | (62,293 | ) | (18,589 | ) | (60,149 | ) | ||||||||
| Net income (loss) attributable to noncontrolling interests | 728 | (29,942 | ) | (163 | ) | (30,207 | ) | |||||||||
| Net loss attributable to Rafael Holdings, Inc. | $ | (4,779 | ) | $ | (32,351 | ) | $ | (18,426 | ) | $ | (29,942 | ) | ||||
| Loss per share | ||||||||||||||||
| Basic and diluted | (0.19 | ) | (1.36 | ) | (0.73 | ) | (1.26 | ) | ||||||||
| Loss per basic common share | $ | (0.19 | ) | $ | (1.36 | ) | $ | (0.73 | ) | $ | (1.26 | ) | ||||
| Weighted average shares in calculation | 25,238,501 | 23,777,493 | 23,131,655 | 23,687,781 | ||||||||||||
FAQ**
How does the recent merger with Cyclo Therapeutics impact Rafael Holdings Inc. Class B RFL's growth strategy and potential for developing treatments for rare diseases like Niemann-Pick Disease Type C1?
What specific financial metrics signal an improvement in Rafael Holdings Inc. Class B RFL's operational efficiency following the rights offering that raised $million earlier this month?
Given the company's cash balance of $37.9 million, how will Rafael Holdings Inc. Class B RFL allocate resources effectively to advance its clinical trials and support ongoing research and development efforts?
What are the anticipated milestones for Rafael Holdings Inc. Class B RFL regarding the Phase 3 TransportNPC study and what implications do these have on market perception and investor confidence?
**MWN-AI FAQ is based on asking OpenAI questions about Rafael Holdings Inc. Class B (NYSE: RFL).
NASDAQ: RFL
RFL Trading
-2.0% G/L:
$1.47 Last:
3,307 Volume:
$1.47 Open:
